男性乳腺癌20例分析

目的：探讨男性乳腺部的病因及影响预后的因素。方法：对我院１９８３年－１９９８年收治的２０例男性乳腺癌患者的临床资料和随访结果进行分析,并结合国内外文献对男性乳腺癌的临床特点,病因和影响预后的因素进行了探讨。结果：有６例患者在发民为症状明显的癌肿之前有乳腺发育。     

男性乳腺癌28例临床分析

男性乳腺癌２８例临床分析任晓平，李青，刘正华，马祥溪男性乳腺癌（以下简称男乳癌）少见，约占全部乳腺癌的１％左右［１～３］其发病率约为０．４９～０．５８／１０万［４，５］。本院及中国医学科学院肿瘤医院自１９７２～１９９２年间收治男乳癌２８例，占同期所有...     

男性乳腺癌30例临床分析

目的探讨男性乳腺癌的临床特点、治疗及预后。方法回顾性分析30例男性乳腺癌患者的临床资料，采用Kaplan—Meier法计算生存率。结果本组5年总生存率为67％。Ⅰ期患者5年生存率为100％，Ⅱ期患者5年生存率为60％，Ⅲ期患者5年生存率为43％，Ⅳ期患者无5年生存病例。单因素分析示肿瘤大小（P=0．006）、腋窝淋巴结转移情况（P=0．013）和肿瘤分期（P=0．004）影响患者预后。Cox回归多因素分析示肿瘤分期（P=0．009）是影响预后的主要因素。结论男性乳腺癌发病率低，发病年龄大，预后差，病理类型以浸润性导管癌多见；以手术为主的综合治疗是男性乳腺癌的治疗模式：其预后与肿瘤分期有关。     

23例男性乳腺癌临床分析

目的　探讨男性乳腺癌的临床特点与预后。方法　分析我院 1986年 8月至 1999年 12月期间收治的 2 3例男性乳腺癌。结果　该病占同期乳腺癌的 1 2 5 % ,Ⅰ、Ⅱ、Ⅲ、Ⅳ期分别为 2例、10例、8例、3例 ,以浸润性导管癌为主 ,腋窝淋巴结转移率 5 6 5 % ,ER、PR受体阳性占 75 % ,5年、10年生存率分别为 61 5 %、2 5 0 % ,Ⅰ～Ⅱ期、腋淋巴结阴性组 5年、10年生存率明显高于Ⅲ～Ⅳ、腋淋巴结阳性组。结论　男性乳腺癌是一种少见恶性肿瘤 ,临床分期、腋淋巴结转移情况是重要的预后指标。以根治术为主辅以放疗、化疗、内分泌治疗是男性乳腺癌的较理想治疗方法     

男性乳腺癌34例生存分析

目的：探讨男性乳腺癌的生物学特性、治疗及预后情况.方法：对1980年3月～2005年3月吉林大学第一医院收治的34例男性乳腺癌患者的临床资料进行回顾性分析,采用Kaplan-Meier法计算生存率、绘制生存曲线.结果：pTNM分期Ⅰ期6例,Ⅱ期24例,Ⅲ期4例,腋窝淋巴结转移率35.3%（12/34）.均采用改良根治术,术后复发率11.8%（4/34）.5年生存率65.3%.结论：与女性乳腺癌相比,男性乳腺癌有其独特的生物学特性,治疗上采用以手术为主的综合治疗.肿瘤分期和激素受体表达等因素是影响预后的主要因素.     

23例男性乳腺癌临床分析

目的 探讨男性乳腺癌的临床特点与预后。方法 分析我院1986年8月至1999年12月期间收治的23例男性乳腺癌。结果 该病占同期乳腺癌的1.25%,Ⅰ、Ⅱ、Ⅲ、Ⅳ期分别为2例、10例、8例、3例，以浸润性导管癌为主，腋窝淋巴结转移率56.5%，ER结阳性组。结论 男性乳腺癌是一种少见恶性肿瘤，临床分期，腋淋巴结转移情况是重要的预后指标。以根治术为主辅以放疗，化疗，内分泌治疗是男性乳腺癌的较理想治疗方法。     

33例男性乳腺癌临床分析

目的　探讨男性乳腺癌的特征、治疗及影响预后的因素。方法　回顾分析了 3 3例男性乳腺癌患者 ,对可能影响预后的因素进行了单因素分析。结果　 5年生存率Ⅰ期 10 0 % ,Ⅱ期 88.2 % ,Ⅲ期 42 .9% ,Ⅳ期 0 %。分析中发现腋淋巴结是否转移、T分期及临床分期对预后有影响。激素受体阳性者生存率高 ,但无阴性对照组。结论　男性乳腺癌预后相对女性乳腺癌无明显差别 ,应采用根治术为主的综合治疗方案 ,内分泌治疗应为一线辅助治疗方案。     

33例男性乳腺癌临床分析

目的:探讨男性乳腺癌的临床特点、诊断、治疗及影响预后的因素。方法:对33例男性乳腺癌的临床资料进行回顾性分析。结果:临床分期I期3例,II期6例,III期19例,IV期5例。9例行根治术,16例行改良根治术,3例单纯乳房切除术。腋窝淋巴结转移阳性者22例,占66.7%.病理类型以浸润性非特殊型癌为主.术后放疗 化疗者14例,化疗 内分泌治疗者9例,单纯放疗和内分泌治疗者分别为5例和3例。结论:男性乳腺癌发病率低、发病年龄高、病程长、恶性程度高、预后差。治疗上应以改良根治性手术为主,辅以放、化疗、内分泌治疗的综合治疗。     

33例男性乳腺癌临床分析

目的 探讨男性乳腺癌的特征、治疗及影响预后的因素。方法 回顾分析了33例男性乳腺癌患者，对可能影响预后的因素进行了单因素分析。结果 5年生存率Ⅰ期100％，Ⅱ期88．2％，Ⅲ期42．9％，Ⅳ期0％。分析中发现腋淋巴结是否转移、T分期及临床分期对预后有影响。激素受体阳性者生存率高，但无阴性对照组。结论 男性乳腺癌预后相对女性乳腺癌无明显差别，应采用根治术为主的综合治疗方案，内分泌治疗应为一线辅助治疗方案。     

男性乳癌31例临床分析

目的探讨男性乳癌的诊断和综合治疗方法.方法对1985年10月～1999年9月收治的31例男性乳癌患者的临床资料进行回顾性分析总结.结果随访至2004年9月,2例局部复发,8例出现远处转移.5年生存率71.0%(22/31).结论男性乳癌是一种少见的恶性肿瘤.诊断主要依靠术后病理,淋巴结转移是主要的预后因素.综合治疗可能有助于提高生存率.     

146例乳腺癌的临床病理特征及预后分析

目的：研究乳腺癌不同的临床、病理特点以及对其生存率的影响。方法：回顾性研究146位乳腺癌患者的不同临床及病理情况下的生存率。结果：淋巴结分期、临床分期及放疗可显著影响总生存期,临床分期、T分期及内分泌治疗对5年无病生存率有显著影响,临床分期对5年无病生存率和总生存率均有显著影响。结论：临床分期对乳腺癌无病生存期及总生存期有重要影响,故早期发现和早期治疗是解决问题、提高生存率的关键。     

男性乳腺癌的研究进展

男性乳腺癌非常少见,约占所有乳腺癌的1％.由于男性乳腺癌发病率远低于女性,大部分的乳腺癌临床研究只纳入女性患者,这导致指导男性乳腺癌临床治疗的前瞻性数据非常有限.因此,男性乳腺癌的治疗决策通常是由女性患者的数据中推断出来的.这种方法并不理想,尤其是考虑到男性和女性各自不同的激素环境.本文就男性乳腺癌的流行病学、临床病理...     

Clinical relevance of biologic factors in male breast cancer

There is ample information on the clinical role of biologic factors in female breast cancer: urokinase-type plasminogen activator (uPA), its receptor uPAR, its inhibitors PAI-1 and PAI-2, cathepsin D and pS2-protein. However such reports are missing or very rare for male breast cancer. We determined the cytosolic levels of oestrogen receptor (ER), progesterone receptor (PgR), cathepsin D, pS2-protein, uPA, uPAR, PAI-1 and PAI-2 of the primary tumour tissues from 40 male breast cancer patients. The tumour levels were compared with those of 180 matched females and 4114 historic females with breast cancer. In male breast tumours the level of PgR was higher, those of uPA, PAI-1, PAI-2 and cathepsin D lower. The tumour level of ER in men was similar to those in the matched and postmenopausal women, but much higher than those in the historic women. Male breast cancer seems to be biologically different from female breast cancer. Correlation of the eight cell biologic factors with disease outcome showed that PAI-1 (p=0.03) was the only independent predictive factor for poor prognosis in male breast cancer.     

Male breast cancer

This study comprises 27 cases of male breast cancer treated at the University Hospital from 1966 through 1978. Its incidence was 0.53% of all cancer in males and 3.2% of all mammary cancers. Mean age was 52 years old. Lump in the breast was the commonest presenting feature in all patients followed by skin ulceration in 44.4% of cases. The average duration of symptoms was 16 months. Twenty-five patients had infiltrating duct carcinoma and two had papillary carcinoma. Two cases were in stage I, 10 in stage II, 11 in stage III, and 4 in stage IV. Of the 12 patients in stages I and II who underwent radical mastectomy, the axillary lymph nodes were pathologically negative in stage I and positive in stage II. The nodes were clinically involved in stages III and IV. Simple mastectomy followed by radiotherapy were used in stage III cancer and all patients in stage IV cancer had only biopsy and palliative chemotherapy. Bilateral orchidectomy followed by estrogen gave only marginal benefit in terms of survival and objective regression. Only four patients, two each in stages I and II, are alive and well for more than five years. These include two cases of papillary carcinoma. Poor prognosis in this series was exclusively determined by axillary lymph node involvement, although other factors such as shorter span of symptoms, younger age group, higher incidence of skin involvement, and invasive nature of carcinoma also appear to be significant.     

A comparative analysis of radiotherapy use and patient outcome in males and females with breast cancer.

BACKGROUND: The aim was to determine whether gender was a significant prognostic factor for post-mastectomy relapse, after accounting for known prognostic factors and delivery of radiotherapy. PATIENTS AND METHODS: All patients diagnosed with invasive breast cancer between 1 January 1989 and 31 December 1998 who had undergone total mastectomy as primary therapy were identified from the British Columbia Cancer Agency's Breast Cancer Outcomes Unit database. Patients with pT4 or M1 disease were excluded. A comparison of patient, tumour and treatment factors was made between males and females. Outcomes were analysed in terms of locoregional-relapse free survival, breast cancer-specific survival and overall survival. RESULTS: Sixty males and 4181 females were identified. Multivariable analysis revealed increased tumour size, positive margin status, delivery of chemotherapy, positive nodal status and male gender to be significantly associated with the use of post-mastectomy radiotherapy. Multivariable analysis revealed tumour size, nodal status, tumour grade and presence of vascular space invasion to be significantly associated with locoregional recurrence. Gender was not a prognostic factor for locoregional recurrence, breast cancer-specific survival or overall survival on univariable or multivariable analysis. CONCLUSIONS: These data suggest that gender is not a prognostic factor in patients undergoing mastectomy for early stage breast cancer. Men having mastectomy for breast cancer should receive adjuvant radiotherapy following guidelines similar to those developed for females.     

青年人乳腺癌176例临床分析

目的探讨青年女性乳腺癌（18～35岁）的临床特点和预后。方法回顾性分析2000～2002年度在本院治疗的青年女性乳腺癌176例,就肿瘤大小、病理类型、TNM分期、淋巴结转移率、雌激素、孕激素受体及C-erbB-2表达等方面与同期就诊的242例中老年女性乳腺癌患者（〉35岁）相比较。结果青年组就诊时间明显晚于中老年组;两组在肿瘤大小及病理类型分布上并无明显差异;组织学分级中,青年组Ⅰ级明显较中老年组少,而Ⅲ级明显多于中老年组,青年组腋窝淋巴结以及内乳淋巴结的转移率均明显高于中老年组,两组比较差异有统计学意义;青年组晚期（Ⅲ、Ⅳ期）病例数比例较中老年组高,青年组ER、PR阳性率低,而C-erbB-2阳性率高,与中老年组相比,差异有统计学意义。结论青年乳腺癌相对于中老年乳腺癌具有临床分期晚,组织学分级高,淋巴结转移率高,激素受体阳性率低,c-erbB-2阳性率高等特点,且复发转移率高,预后差。     

Cdc20 and securin overexpression predict short-term breast cancer survival

Background:

Cdc20 is an essential component of cell division and responsible for anaphase initiation regulated by securin degradation. Cdc20 function is strongly regulated by the spindle assembly checkpoint to ensure the timely separation of sister chromatids and integrity of the genome. We present the first results on Cdc20 in a large clinical breast cancer material.

Methods:

The study was based on 445 breast cancer patients with up to 20 years of follow-up (mean 10.0 years). DNA content was determined by image cytometry on cell imprints, and Cdc20 and securin immunohistochemistry on tissue microarrays of breast cancer tissue.

Results:

In our results, high Cdc20 and securin expression was associated with aneuploid DNA content. In prognostic analyses, high Cdc20 immunoexpression alone and in combination with high securin immunoexpression indicated aggressive course of disease and up to 6.8-fold (P<0.001) risk of breast cancer death. Particularly, high Cdc20 and securin immunoexpression identified a patient subgroup with extremely short, on average 2.4 years, breast cancer survival and triple-negative breast cancer (TNBC) subtype.

Conclusions:

We report for the first time the association of high Cdc20 and securin immunoexpression with extremely poor outcome of breast cancer patients. Our experience indicates that Cdc20 and securin are promising candidates for clinical applications in breast cancer prognostication, especially in the challenging prognostic decisions of TNBC.     

男性乳腺癌的临床特征及治疗(附16例)

目的　探讨男性乳腺癌的临床特点 ,治疗方式以及影响预后的因素。方法　对我院 1982年至1997年间收治的 16例男性乳腺癌的症状、体征、影像学表现以及手术治疗、放疗、化疗、内分泌治疗效果等进行综合分析。结果　 16例患者经手术、放疗、化疗及内分泌等综合治疗后 ,存活 5年以上者 9例 ,占5 6 3% ,存活 10年以上者 3例。结论　男性乳腺癌较少见 ,病程长 ,恶性程度高 ,预后一般较女性乳腺癌差 ,早期诊断及综合治疗是取得良好预后的关键。